[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Abstract, edited.]
Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient
Sarah C J Jorgensen, Philip McDonald, Ryan P Mynatt, Jason M Pogue, Stephen A Lerner, Sorabh Dhar, Hossein Salimnia, Michael J Rybak
Journal of Antimicrobial Chemotherapy, dky346, https://doi.org/10.1093/jac/dky346
Published: 04 September 2018
The prevalence of carbapenem-resistant Enterobacteriaceae (CRE) has increased dramatically over the past two decades, fuelling speculation that we are nearing the ‘post-antibiotic era’ and attesting to the critical need for novel antibiotics with activity against MDR pathogens.1 In 2015 the US FDA approved ceftazidime/avibactam for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections caused by MDR Gram-negative bacteria.2 The introduction of ceftazidime/avibactam represented significant progress in the treatment of CRE, with accumulating real‐world data demonstrating improved efficacy and safety compared with older, more toxic antibiotics.3–5However, treatment failure rates as high as 30%–50% have been…
Issue Section: Research letter
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: email@example.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Keywords: Antibiotics; Drugs Resistance; Carbapenem; Serratia marcescens; Enterobacter aerogenes; Bacteremia; Meropenem; Vaborbactam.